Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cervarix Lot-to-Lot Consistency in Healthy Females
NCT00250276Phase 3Completed
- Sponsor
- GSK
- Start
- Oct 2005
- Primary completion
- Mar 2007
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 3
01
Overview
A Phase 3 trial of Human papillomavirus type 16 L1 capsid protein residues 2-471 antigen in human papillomavirus infection, Cervical Cancer (CC), sponsored by GSK. Started Oct 2005; status: completed.
02
Drugs
Human papillomavirus type 16 L1 capsid protein residues 2-471 antigen
03
Conditions
human papillomavirus infectionCervical Cancer (CC)
Beyond the preview
Go deeper on NCT00250276.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00250276.